Eli Lilly's Experimental Drug Reduces Heart Disease Risk by 94% for a Year
Eli Lilly's experimental drug, lepodisiran, has shown promising results in reducing the risk of heart disease by 94% for up to a year, according to a phase 1 trial. The drug significantly lowered levels of a heart disease-linked protein, Lipoprotein(a), to undetectable levels for 48 weeks, with the highest dose reducing it by up to 96% within the first two weeks. The study raises hope for individuals at high risk for heart disease due to their genetic makeup. Additionally, a separate study presented at the American Heart Association revealed that Novo Nordisk's diabetes-turned-weight-loss drug, Wegovy, can reduce the risk of severe heart problems by 20%.